Health News Releases

  • Today November 13
March 23, 2015 11:40
Oral OTEZLA® (apremilast) Long-Term Safety and Efficacy Data in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD
Celgene Corporation (NASDAQ: CELG) today announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla® (apremilast) were presented at the
March 23, 2015 11:20
Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference
Today Biogen Idec (NASDAQ:BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile
March 19, 2015 13:55
Queen Mary University of London Wins 2014 Terumo BCT Plasma Exchange Innovation Award
Terumo BCT is pleased to announce that Queen Mary University of London (QMUL) has been named the recipient of the 2014 Plasma Exchange Innovation Award (www.plasmaexchangegrant.com). The award is part
March 19, 2015 09:45
Phase II Data for Celgene’s Investigational Oral GED-0301 for Patients with Active Crohn’s Disease Published in New England Journal of Medicine
Celgene Corporation (NASDAQ:CELG) today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of three doses of GED-0301 (mongersen) in patients with active Crohn'
March 17, 2015 10:20
Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment
For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces two analyses from the GLORIA™-AF Registry Program examining the use of anticoagulant treatments for stroke prevention in pa
March 17, 2015 08:50
Apgujeong YK Plastic Surgery Awarded Medical Tour Contribution Plaque for Its Excellence in Sanitary Inspection
Apgujeong YK Plastic Surgery was selected as an outstanding medical institution in sanitary inspection for operating rooms for its excellent hygienic conditions and honored with a Medical Tour Contrib
March 12, 2015 10:55
Nestlé Skin Health Announces Leadership Team
Nestlé Skin Health today announced organizational changes at top management level to support the company’s expanded market opportunity and ambition. “Our goal is to grow the number of people the compa
March 06, 2015 11:55
Modern Day Cold and Flu Experience Includes 35 Billion Sick Days and Coping on Social Media, According to Vicks® Global Survey
A new multi-country survey by Vicks®, the world’s #1 selling cough and cold brand*, revealed that the average person spends an astonishing three years of his/her life with a cold**. Globally consumers
March 04, 2015 10:15
Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada
For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces that idarucizumab has been submitted for approval of marketing authorisation to the European Medicines Agency (EMA), U.S. F
March 03, 2015 17:00
ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved ABRAXANE® (paclitaxel formulated as albumin-
February 26, 2015 13:55
Quintiles Receives Third Technology Security Award from IDG’s CSO Magazine
Quintiles (www.quintiles.com/news) announced today that it has been named to the 2015 CSO50 by IDG's CSO magazine (www.csoonline.com) in recognition of the company’s risk mitigation strategy managing
February 26, 2015 13:45
Gore Global Registry for Endovascular Aortic Treatment Reaches 2,500 Enrolled Patients
W. L. Gore & Associates, Inc. (Gore, www.goremedical.com) reports that more than 2,500 patients have been enrolled in the Gore Global Registry for Endovascular Aortic Treatment (GREAT). The registry i
February 25, 2015 14:40
Management Buy out of Synexus Backed by LDC; the Deal Will Enable It to Further Expand Its Global Network
Today (Monday 23rd February 2015) Synexus, the world’s largest multi-national company dedicated to the recruitment and running of clinical trials at its own research centres across the globe, complete
February 25, 2015 13:25
Quintiles Appoints Elgar Peerschke as President of Advisory Services
Quintiles today announced the appointment of Elgar Peerschke to serve as president, Advisory Services. In this role, Peerschke is responsible for leading Quintiles’ Advisory Services organization and
February 24, 2015 14:00
Second Sight to Present at the 27th Annual ROTH Conference on March 9, 2015
Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind pati
February 24, 2015 13:30
Ferring Pharmaceuticals Acquires Novel Drug Delivery Technology From CTCBIO Inc.
Ferring Pharmaceuticals announced today that it has signed an agreement with CTCBIO Inc. of Seoul, South Korea to acquire rights to a novel oral drug delivery technology. Ferring’s success in devel
February 24, 2015 11:55
FDA Grants Seven Years’ Market Exclusivity to Eagle Pharmaceuticals’ Ryanodex for the Treatment of Malignant Hyperthermia
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today confirmed that the U.S. Food and Drug Administration (FDA) has granted seven years of market exclusivity in the U.S. to Ryano
February 23, 2015 23:25
Quintiles Named to FORTUNE Magazine's 2015 List of “World’s Most Admired Companies”
Quintiles, the world’s largest biopharmaceutical services company, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for 2015. Quintiles is ranked third overall in FORTUNE’
February 23, 2015 11:55
REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment o
February 23, 2015 11:05
Ferring Pharmaceuticals acquires two phase III ready orthobiologic product candidates from BioSET
Ferring Pharmaceuticals announced today that it has acquired the assets of BioSurface Engineering Technologies, Inc. (BioSET), including two phase III ready orthobiologic product candidates designed t
February 17, 2015 16:00
CellProthera, Pioneer in Cell Regenerative Therapy, Awarded the 2014 UBISTART Prize
CellProthera has been awarded the 2014 UBISTART prize, under the aegis of UBIFRANCE and the Galien Foundation based in New York. This initiative rewards innovative French start-ups for making major ad
February 17, 2015 14:00
Eppendorf Announces New CryoCube® Ultra-Low Temperature Freezers
The new CryoCube (www.nbsc.com/freezers) F570, F570h, FC660, and FC660h ultra-low temperature freezers combine maximum sample security with improved functionality. New advancements decrease power cons
February 13, 2015 13:10
Manufacturing Authorization of Gene Therapy Medicinal Products Granted to CELLforCURE, the LFB Group Subsidiary Specialized in Innovative Therapies
CELLforCURE, a pharmaceutical establishment since October 2013 for the manufacturing of cell therapy medicinal products, was granted a new manufacturing authorization on January 30th, 2015. Delivered
February 12, 2015 15:25
Addition of Stent Thrombectomy in Treatment of Acute Ischemic Stroke Patients Reduces Disability in Global Studies
Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire™ D
February 10, 2015 16:00
Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival
Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 trial evaluating the safety and efficacy of ixazom
25 per page50 per page75 per page100 per page